Stryker (SYK) Gets a Buy Rating from BTIG
BTIG analyst Ryan Zimmerman maintained a Buy rating on Stryker (SYK) yesterday and set a price target of $213.00. The company’s shares closed last Thursday at $186.43.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 13.4% and a 56.7% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Staar Surgical Company, and Zimmer Biomet Holdings.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Stryker with a $203.45 average price target.
See today’s analyst top recommended stocks >>
Stryker’s market cap is currently $72.22B and has a P/E ratio of 33.80. The company has a Price to Book ratio of -141.81.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SYK in relation to earlier this year. Most recently, in March 2020, Srikant Datar, a Director at SYK bought 1,000 shares for a total of $59,700.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stryker Corp. engages in providing medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The Medsurg segment deals with surgical equipment and navigation systems, endoscopy, patient handling, and reprocessed medical devices. The Neurotechnology and Spine segment pertains to spinal implants and neurovascular products. The company was founded by Homer H. Stryker in 1941 and is headquartered in Kalamazoo, MI.